0001968582-23-000263.txt : 20230620 0001968582-23-000263.hdr.sgml : 20230620 20230620165255 ACCESSION NUMBER: 0001968582-23-000263 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230620 DATE AS OF CHANGE: 20230620 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 231025958 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: Session R.A. II CENTRAL INDEX KEY: 0001701846 FILING VALUES: FORM TYPE: 144 MAIL ADDRESS: STREET 1: C/O AVEXIS, INC. STREET 2: 2275 HALF DAY ROAD, SUITE 200 CITY: BANNOCKBURN STATE: IL ZIP: 60015 144 1 primary_doc.xml 144 0001701846 XXXXXXXX LIVE 0001806310 Taysha Gene Therapies Inc 001-39536 3000 Pegasus Park Drive Suite 1430 Dallas TX 75247 212-612-0000 R.A. Sessions II Affiliate Common J.P. Morgan Securities LLC

390 Madison Avenue 6th Floor New York NY 10017

1006000 699572.4 64178567 06/20/2023 Nasdaq Common 09/23/2020 Founder Shares Issuer N 1006000 09/23/2020 N/A Y 06/20/2023 /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for R.A. Sessions II